A new strategy for mapping epitopes of LACK and PEPCK proteins of Leishmania amazonensis specific for major histocompatibility complex class I

dc.creatorSena, Edlainne Pinheiro Ferreira
dc.creatorHardoim, Daiana de Jesus
dc.creatorCardoso, Flavia de Oliveira
dc.creatord’Escoffier, Luiz Ney
dc.creatorSoares, Isabela Ferreira
dc.creatorCarvalho, João Pedro Rangel da Silva
dc.creatorAngnes, Ricardo Almir
dc.creatorFragoso, Stenio Perdigão
dc.creatorAlves, Carlos Roberto
dc.creatorDe Simone, Salvatore Giovanni
dc.creatorLima Junior, Josué da Costa
dc.creatorBertho, Alvaro Luiz
dc.creatorValle, Tânia Zaverucha do
dc.creatorSilva, Franklin Souza da
dc.creatorCalabrese, Kátia da Silva
dc.date2023-04-08T16:00:00Z
dc.date2023-04-08T16:00:00Z
dc.date2023
dc.date.accessioned2023-09-26T20:50:25Z
dc.date.available2023-09-26T20:50:25Z
dc.identifierSENA, Edlainne Pinheiro Ferreira et al.A new strategy for mapping epitopes of LACK and PEPCK proteins of Leishmania amazonensis specific for major histocompatibility complex class I. International Journal of Molecular Sciences, v. 24, 5972, p. 1-15, Mar. 2023.
dc.identifier1422-0067
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/57717
dc.identifier10.3390/ ijms24065972
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8864804
dc.descriptionLeishmaniasis represents a complex of diseases with a broad clinical spectrum and epidemiological diversity, considered a major public health problem. Although there is treatment, there are still no vaccines for cutaneous leishmaniasis. Because Leishmania spp. is an intracellular protozoan with several escape mechanisms, a vaccine must provoke cellular and humoral immune responses. Previously, we identified the Leishmania homolog of receptors for activated C kinase (LACK) and phosphoenolpyruvate carboxykinase (PEPCK) proteins as strong immunogens and candidates for the development of a vaccine strategy. The present work focuses on the in silico prediction and characterization of antigenic epitopes that might interact with mice or human major histocompatibility complex class I. After immunogenicity prediction on the Immune Epitope Database (IEDB) and the Database of MHC Ligands and Peptide Motifs (SYFPEITHI), 26 peptides were selected for interaction assays with infected mouse lymphocytes by flow cytometry and ELISpot. This strategy identified nine antigenic peptides (pL1-H2, pPL3-H2, pL10-HLA, pP13-H2, pP14-H2, pP15-H2, pP16-H2, pP17-H2, pP18-H2, pP26-HLA), which are strong candidates for developing a peptide vaccine against leishmaniasis.
dc.formatapplication/pdf
dc.languageeng
dc.publisherMDPI
dc.rightsopen access
dc.subjectLeishmaniose cutânea
dc.subjectEpítopos T
dc.subjectPeptídeos
dc.subjectVacina
dc.subjectBioinformática
dc.subjectHLA
dc.subjectH2Db
dc.subjectMHC I
dc.subjectTetrâmero
dc.subjectCutaneous leishmaniasis
dc.subjectTepitopes
dc.subjectPeptides
dc.subjectVaccine
dc.subjectBioinformatics
dc.subjectHLA
dc.subjectH2Db
dc.subjectMHC I
dc.subjectTetramer
dc.titleA new strategy for mapping epitopes of LACK and PEPCK proteins of Leishmania amazonensis specific for major histocompatibility complex class I
dc.typeArticle


Este ítem pertenece a la siguiente institución